{"ticker": {"uuid": "b58a5b41-5e8b-474a-a14a-af1b858bad55", "symbol": "CNTB", "name": "Connect Biopharma Holdings Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lake Street Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $9", "summary": "Lake Street maintained a Buy rating on Connect Biopharma (CNTB.US) and kept its target price at $9.", "url": "https://www.moomoo.com/news/post/73023632/lake-street-maintains-connect-biopharma-cntbus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-15T17:10:28", "published_display": "15 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Connect Biopharma Holdings (CNTB) Receives a New Rating from Oppenheimer", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQTElsSVdFNC1PWXhQa2xnazJraFc0U1RYYkV3R0FLaWhvV0pDVU10eE5yVmpTRDJkS2hhYjhmZUFwVDBqTDRCVGJtNl9mcVVMWWk3NFgyckFadjBFZjJBSGZoUTdtRXo3azg3M3hWcUx6OWpnTkZaem0wVFJIbjRZWFc1TWJXU0VlLUZrYzA5OGtxRjFublFoZ0lGeFZiYWh3UmxCLXJQTVNnNVJ5T25hYnZpY01WeWJMZ0w4YlJ6U0YyNWFOZUNJaHpIOXpOSGhPRExlQ0QteEpkMVpVVkNVeWNVcXV2Zw?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-10T17:38:00+00:00", "published_display": "10 Jul 2026 17:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Initiates Connect Biopharma(CNTB.US) With Buy Rating, Announces Target Price $8", "summary": "Oppenheimer has initiated coverage on Connect Biopharma (CNTB.US) with a 'Buy' rating. The firm has set a price target of $8 for the company's stock, indicating a positive outlook for its future performance.", "url": "https://www.moomoo.com/news/post/72730067/oppenheimer-initiates-connect-biopharma-cntbus-with-buy-rating-announces-target", "source_name": "Moomoo", "published_at": "2026-07-10T14:10:24", "published_display": "10 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer initiates Connect Biopharma stock with outperform rating", "summary": "Oppenheimer has initiated coverage on Connect Biopharma (NASDAQ: CNTB) with an Outperform rating and an $8.00 price target, citing the company's lead drug rademikibart for inflammatory respiratory diseases. The drug, a next-generation human IgG4 anti-IL-4R\u03b1 antibody, is currently", "url": "https://www.investing.com/news/analyst-ratings/oppenheimer-initiates-connect-biopharma-stock-with-outperform-rating-93CH-4784101", "source_name": "Investing.com", "published_at": "2026-07-09T13:40:23", "published_display": "09 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Initiates Connect Biopharma at Outperform With $8 Price Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNcUZHdC14ZmtORGFBNlRHN2I0UkxBNF92emswWDkyb1k0SkQyTDhBOE54VHc5a3MtZTVickhKWkEtZHktdkgtS3lqbXdFaVRqb3EycWlOODFadFZmaDRfODVsRGRWNzlKcVRsMXhOanBzTXlLYW5SZlhmSzlzbzNHOHNqZ3BYZkF1RDJyQzZ2WjByb1lXVnZPclE5ZGhyN3hJMkw0TXVBZC1IcXBCdVJFVzdYQlFPNGcwM255U19MZjJGcTct?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-09T12:39:18+00:00", "published_display": "09 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer initiates Connect Biopharma stock with outperform rating By Investing.com", "summary": "Oppenheimer has initiated coverage on Connect Biopharma Holdings Ltd (NASDAQ: CNTB) with an Outperform rating and an $8.00 price target. The company is developing rademikibart for inflammatory respiratory diseases, with Phase 2 trial results for asthma and COPD expected in the se", "url": "https://ng.investing.com/news/stock-market-news/oppenheimer-initiates-connect-biopharma-stock-with-outperform-rating-93CH-2593202", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T13:10:39", "published_display": "09 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CNTB - Connect Biopharma Holdings Ltd Dividends", "summary": "This page provides detailed financial information for Connect Biopharma Holdings Ltd (CNTB), including dividend data, key financial ratios, performance metrics, and insider/institutional ownership. The company's last close was $2.36, experiencing a 4.07% decrease. It also shows v", "url": "https://finviz.com/stock?t=CNTB&ta=1&p=d&ty=dv&b=2", "source_name": "Finviz", "published_at": "2026-07-06T00:39:51", "published_display": "06 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CNTB - Connect Biopharma Holdings Ltd Latest SEC Filings", "summary": "This article provides the latest SEC filing information for Connect Biopharma Holdings Ltd (CNTB), alongside comprehensive financial data and performance metrics. It includes details such as market capitalization, income, sales, various financial ratios, insider and institutional", "url": "https://finviz.com/stock?t=CNTB&p=m&ty=lf&page=3", "source_name": "Finviz", "published_at": "2026-07-04T09:40:30", "published_display": "04 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Connect Biopharma Holdings Ltd For: 1 July By Investing.com", "summary": "This article provides details about a Form 4 filing for Connect Biopharma Holdings Ltd, dated July 1st. It highlights the stock symbol CNTB and its performance, showing a 2.93% increase. The piece is brief and primarily serves as a notification of the filing.", "url": "https://uk.investing.com/news/stock-market-news/form-4-connect-biopharma-holdings-ltd-for-1-july-93CH-4753717", "source_name": "Investing.com UK", "published_at": "2026-07-02T11:39:31", "published_display": "02 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma (CNTB) director granted 3,738 fully vested shares as fees", "summary": "Connect Biopharma Holdings Ltd director Dr. Kleanthis Gabriel Xanthopoulos was granted 3,738 fully vested Ordinary Shares on June 30, 2026. These shares were issued in lieu of a portion of his 2026 annual board cash retainers for service during Q2 2026. Following this award, Dr. ", "url": "https://www.stocktitan.net/sec-filings/CNTB/form-4-connect-biopharma-holdings-ltd-insider-trading-activity-e8fe63c2cd17.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:39:23", "published_display": "01 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma (NASDAQ: CNTB) director receives 6,718-share award as 2026 board compensation", "summary": "Connect Biopharma (NASDAQ: CNTB) director Jean I. Liu was granted 6,718 ordinary shares as compensation for her 2026 annual board service during Q2 2026, in lieu of cash retainers. This award, calculated based on the average closing share price for 30 days preceding June 30, 2026", "url": "https://www.stocktitan.net/sec-filings/CNTB/form-4-connect-biopharma-holdings-ltd-insider-trading-activity-cbf895c6e3ce.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:39:23", "published_display": "01 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings Limited(NasdaqGM: CNTB) added to Russell Microcap Index", "summary": "Connect Biopharma Holdings Limited (NasdaqGM: CNTB) has been added to the Russell Microcap Index. This follows a previous announcement that the company was also added to the Russell 3000E Growth Benchmark. The news highlights the company's progress and increased visibility within", "url": "https://www.marketscreener.com/news/connect-biopharma-holdings-limited-nasdaqgm-cntb-added-to-russell-microcap-index-ce7f5fdedd89f120", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:39:49", "published_display": "29 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings Limited(NasdaqGM:CNTB) added to Russell 3000 Growth Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOLWYxNk9oQVk3akVESTdZU2V5SFBIR2ZjUFhwNm9Ob0hkOFZKeUdER1dhT1d6Rm03ejBLenJKaGR6OEstZmRJbUR3dlFyUmZJNUJidGIzOHF6bTJKVWNuMTRLOXJGcEFYaVFZRVA1WmVjaFoyV3pPdmszajE2NENTWHlEa0ZuM0xqYmtVdmRueWd3MHJBVjN5QmlHUlhndEl0RUZSX2EtZXJTalVJMFViNi1pRjJEMDhoa1pNR3I4cmJrdm5xdWlTSDZDZnRQZUJnMDUxdlVENA?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings Limited(NasdaqGM:CNTB) added to Russell Small Cap Completeness Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxPZlFoX1NveDlMZGlqeFdFRl85VlRYYUNjbW9oU1RyVlkxM1o4X3pSOWZCUGRaTjJuV2QyczFSM1R2aVVDX0pyOEhMRng1WTZPcmNyVEs0TzFGNHVBS3kzQ0lsdDlGTlhIR1JZa1B2V2hHOVJzN3JlSFpGN3dKTzJ3RnpCVGFVUXVSWGIwSmM1R2pka1dZTTlEZ0I5MUtESkJHQkFIODZUS210UFZ6LXB1N0tDTFF1b0ZiZEZURGhwV3lQVXFUZnRSRzNGSjNxRnEtVHUzd01rTFBSQ3I0Ykx5Qw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler initiates Connect Biopharma stock with overweight rating By Investing.com", "summary": "Piper Sandler initiated coverage on Connect Biopharma Holdings Ltd (NASDAQ:CNTB) with an Overweight rating and a $7.00 price target. The firm highlighted rademikibart's potential as a unique biologic for acute asthma and COPD exacerbations, expecting significant sales growth and ", "url": "https://ca.investing.com/news/stock-market-news/piper-sandler-initiates-connect-biopharma-stock-with-overweight-rating-93CH-4708850", "source_name": "Investing.com Canada", "published_at": "2026-06-26T09:09:42", "published_display": "26 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Initiates Connect Biopharma(CNTB.US) With Buy Rating, Announces Target Price $7", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOOHljWTdtOVMydERUTjhrTmtFRFdJRm1EWUlFa0lpUDN6b3I2REdUMmozZEkxNFJUNC03SzFLdTF5aTBFdUFOZzRObHBaZ0lILVMxRXozeEdnZ1RMM2FsWEw1Nll4UEhGTlNqeTZXREw5c2xydkl5c0c4azU1WUthbWZiRG1YRi1BcEM5S3ZOdlNfdk0wb3hYVGdsYkFaYWY5bHpVaTl5MjZ5N1UzUE1UY3Z0QUNHWm8?oc=5", "source_name": "Moomoo", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler initiates Connect Biopharma stock with overweight rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNT25nOWhNVXAxV3VWUE5nN0luLXdJYTR6NXg5VEQzWjFUYURuTWxwZ0pPTFVYU2JZWGJ4ZF8xRzVYNTAtSE9BdFRVZm1OMS00dDZxV2d0eFAwVE5NRFZadVl5cmdKMGc2dHpXd29XYjFuU0x4cGNYQkZSMVMxODdfWE95RGI3eUhjUVUyc0JLdnc1WDhMNzdXNDZYbjBVcUc2dkNrSGR5aHlLMm40X0lLRmtUSnNkb09CWjRhR1pPTEhOaklHR20wWEpR?oc=5", "source_name": "Investing.com", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings Ltd. Actuals & Estimates (NASDAQ:CNTB)", "summary": "This article provides an overview of Connect Biopharma Holdings Limited (NASDAQ: CNTB) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It details financial data such as earnings per share, revenue, net income, and EBITDA, ", "url": "https://www.tradingview.com/symbols/NASDAQ-CNTB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:09:42", "published_display": "26 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Buy on Connect Biopharma stock at $7", "summary": "H.C. Wainwright has reiterated a Buy rating for Connect Biopharma Holdings Ltd (NASDAQ:CNTB) with a $7.00 price target, though InvestingPro data suggests the stock is currently overvalued. The company is actively progressing with its Phase 2 Seabreeze STAT Asthma and COPD studies", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-on-connect-biopharma-stock-at-7-93CH-4760390", "source_name": "Investing.com", "published_at": "2026-06-25T11:40:13", "published_display": "25 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings Ltd (CNTB) Valuation: PE, PB & Fair Value Analysis", "summary": "Connect Biopharma Holdings Ltd (CNTB) currently holds a valuation score of 6.10, ranking 355 out of 387 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -1.79, indicating it is -34.93% below its recent high and -131.62% above its recent low. Key", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cntb/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-24T07:42:05", "published_display": "24 Jun 2026 07:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings Ltd (CNTB) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Connect Biopharma Holdings Ltd (CNTB) has an earnings forecast score of 8.67, ranking 71st in the Biotechnology & Medical Research industry, with an average price target of $7.50. Analysts, based on 7 ratings, largely recommend a \"Buy\" for the stock, forecasting an expected reven", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cntb/earnings", "source_name": "TradingKey", "published_at": "2026-06-23T07:42:05", "published_display": "23 Jun 2026 07:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Buy on Connect Biopharma stock at $7 By Investing.com", "summary": "H.C. Wainwright has reiterated a Buy rating and a $7.00 price target for Connect Biopharma Holdings Ltd (NASDAQ:CNTB), noting a significant upside potential from its current trading price of $2.08. The firm highlighted that enrollment for the Phase 2 Seabreeze STAT COPD study is ", "url": "https://m.in.investing.com/news/stock-market-news/hc-wainwright-reiterates-buy-on-connect-biopharma-stock-at-7-93CH-5461553?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-06-18T17:09:35", "published_display": "18 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings Ltd (CNTB) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Connect Biopharma Holdings Ltd (CNTB), listing its major shareholders and their respective proportions. It also breaks down shareholder types by category, such as venture capital and corporations. Additionally, the report provides", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cntb/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:56", "published_display": "18 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings Ltd (CNTB) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for Connect Biopharma Holdings Ltd (CNTB). It states that the company has distributed $0.00 in dividends over the past five years and shows no historical data for stock splits. The stock's current price and mar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cntb/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:11:11", "published_display": "17 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma stock rises after Phase 2 asthma study enrollment By Investing.com", "summary": "Connect Biopharma Holdings Ltd (NASDAQ: CNTB) shares rose 8% after announcing the completion of enrollment in its Phase 2 Seabreeze STAT Asthma study for rademikibart. The company expects to report topline data from this study in early September 2026, followed by results from its", "url": "https://ng.investing.com/news/stock-market-news/connect-biopharma-stock-rises-after-phase-2-asthma-study-enrollment-93CH-2563373", "source_name": "Investing.com Nigeria", "published_at": "2026-06-17T15:26:00", "published_display": "17 Jun 2026 15:26", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma completes asthma trial enrollment", "summary": "Connect Biopharma Holdings Limited has completed enrollment for its Phase 2 Seabreeze STAT Asthma study, evaluating rademikibart for acute asthma exacerbations. The company expects to release topline data from the asthma study in early September 2026 and plans to meet with the FD", "url": "https://www.investing.com/news/company-news/connect-biopharma-completes-asthma-trial-enrollment-93CH-4747438", "source_name": "Investing.com", "published_at": "2026-06-17T14:11:11", "published_display": "17 Jun 2026 14:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/connect-biopharma-announces-completion-enrollment-130000017.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T13:00:00+00:00", "published_display": "17 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Completes Enrollment in Phase 2 Seabreeze STAT Asthma Study and Anticipates Upcoming COPD Study Data", "summary": "Connect Biopharma Holdings Limited has completed enrollment in its Phase 2 Seabreeze STAT Asthma study for rademikibart, a next-generation antibody for asthma exacerbations. The company expects to report topline results from the asthma study by early September 2026, with data fro", "url": "https://www.quiverquant.com/news/Connect+Biopharma+Completes+Enrollment+in+Phase+2+Seabreeze+STAT+Asthma+Study+and+Anticipates+Upcoming+COPD+Study+Data", "source_name": "Quiver Quantitative", "published_at": "2026-06-17T13:12:00", "published_display": "17 Jun 2026 13:12", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Announces Completion of Enrollment of", "summary": "Connect Biopharma has announced the completion of enrollment for its Phase 2 Seabreeze STAT Asthma study, evaluating rademikibart for acute asthma exacerbations. The company expects to report topline data from this study in early September 2026 and is on track to complete enrollm", "url": "https://www.globenewswire.com/news-release/2026/06/17/3313482/0/en/connect-biopharma-announces-completion-of-enrollment-of-phase-2-seabreeze-stat-asthma-study-evaluating-rademikibart-for-the-treatment-of-acute-exacerbations-in-asthma.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T13:10:33", "published_display": "17 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 94, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma finishes asthma study enrollment, data due in September", "summary": "Connect Biopharma has completed enrollment for its Phase 2 Seabreeze STAT Asthma study, which evaluates rademikibart for acute asthma exacerbations, and expects topline data in early September 2026. The company also anticipates completing enrollment for a related COPD study this ", "url": "https://www.stocktitan.net/news/CNTB/connect-biopharma-announces-completion-of-enrollment-of-phase-2-21qe7f6d4kk1.html", "source_name": "Stock Titan", "published_at": "2026-06-17T13:10:33", "published_display": "17 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director-linked fund boosts Connect Biopharma (NASDAQ: CNTB) stake", "summary": "An entity linked to Connect Biopharma director James Huang, Panacea Venture Healthcare Fund II, L.P., purchased 150,000 Ordinary Shares of Connect Biopharma (NASDAQ: CNTB) at a weighted average price of $2.4774 per share. This transaction increases the fund's indirect holdings to", "url": "https://www.stocktitan.net/sec-filings/CNTB/form-4-connect-biopharma-holdings-ltd-insider-trading-activity-5b23ed14ca15.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:09:52", "published_display": "02 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Connect Biopharma Holdings Ltd SEC Filing", "summary": "Connect Biopharma Holdings Ltd (NASDAQ: CNTB) announced that its F-3 shelf registration statement became effective on June 1, 2026, at 4:00 PM. The filing, dated June 2, 2026, specifies the company's CIK as 0001835268 and file number 333-295921. This indicates the company can off", "url": "https://www.stocktitan.net/sec-filings/CNTB/effect-connect-biopharma-holdings-ltd-sec-filing-f9d1dc4ab6dd.html", "source_name": "Stock Titan", "published_at": "2026-06-02T10:09:52", "published_display": "02 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings (NasdaqGM:CNTB) Stock Forecast & Analyst Predictions", "summary": "Connect Biopharma Holdings (CNTB) is projected for significant growth, with earnings forecast to increase by 2.2% and revenue by 52.7% per annum. The company's lead product, rademikibart, has shown promising results in clinical trials for atopic dermatitis, asthma, and COPD, with", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cntb/connect-biopharma-holdings/future", "source_name": "Simply Wall Street", "published_at": "2026-05-26T21:39:39", "published_display": "26 May 2026 21:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord Genuity Initiates Connect Biopharma at Buy With $6 Price Target", "summary": "Canaccord Genuity has initiated coverage on Connect Biopharma (NASDAQ: CNTB) with a Buy rating and a price target of $6. The firm's positive outlook suggests confidence in the biopharmaceutical company's future performance and potential for stock appreciation.", "url": "https://www.moomoo.com/news/post/70566398/canaccord-genuity-initiates-connect-biopharma-at-buy-with-6-price?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-26T19:09:29", "published_display": "26 May 2026 19:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Touts Rademikibart\u2019s Edge as SEABREEZE Data Looms in 2026", "summary": "Connect Biopharma's CEO, Barry Quart, highlighted the differentiated clinical profile of their rademikibart program, an IL-4 receptor alpha monoclonal antibody, as the company anticipates SEABREEZE study data in mid-2026. Quart discussed the drug's abilities to lower eosinophils ", "url": "https://es.tradingview.com/news/marketbeat:3e81f6b06094b:0-connect-biopharma-touts-rademikibart-s-edge-as-seabreeze-data-looms-in-2026/", "source_name": "TradingView", "published_at": "2026-05-25T09:09:06", "published_display": "25 May 2026 09:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Connect Biopharma Holdings (NASDAQ:CNTB) Must Use Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Could Be Quite Risky", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/companies-connect-biopharma-holdings-nasdaq-134008153.html", "source_name": "Simply Wall St.", "published_at": "2026-05-15T13:40:08+00:00", "published_display": "15 May 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxOd2lvRDFQbVQtV3R0NDcxN2JRc08tVC1xdDBiNW93ZXN1TmJWakdNcmtiOE9PNWpCYjZtQ0ZKQk10MjI0clRHbmpGQzdCSlE3T09GdzhuVUNZRDRHVUJYeVJVVktRQjlXN0I2TWduM0ktdmFkVjhLY01jWFkyM3RYWmVjZDVQMmJwcHloWVVicS1MdG9QQjFqMWo3RG5yOU1rQVBXTGltdXZTTV9yUTJnTVJmeGJ0MW5yRjROTHNBc29HNU1yek5CUVpzRkptNDZCQXZsa3JmdTZJejVuQzhnRzZrUXQ5WWJ3RUc2VWFQMkpBdEJ5enhn?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxNRk1EUDV6US1sakdvWTBiV2llQkktWGF1cnY0MFAtVUZpdGtoOWJmMDJ6bHhOM2RrMkFXVGxsaGR2YmE5cXhRdUQ0Skdia25LQ0RjZjJsNlBNd0NGSS1OSVNUSHZmOC1DLXAtZVk3UWtrR1NWTnY3aURtU1R2dF9oSG96dnp0Sm9QajJUeXZURkp6UHRSZjMtdVFSZUs0bkI2QmtDMDBGOUc1enJ6SzE4R2hzejlGa2tEbzlod0F0TVl4bkxjZGxJX0xyWWJ0Q1NncG1ZcVdTbXpoMTFacjhKQ05jYnlLUEdHaFJwcXlXUkx1cTdDUUE?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Connect Biopharma Announces Enrollment in Phase 2 Seabreeze", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAJBVV95cUxPSlVKaUJZR0Y5d3Z4OWNXejJ4V0taT2RObGpjNGgySmFScTljWWZGTnBRbW5TaXlia3FRb0pkYldFMkxaYkRqUWdiZXVnTXNDVDZ6YldsOE5hSnBSeWRIYlFqdldfLVhLN3BBdkVSNlNWS3dnNmZoN2FqLWI5TGgzV0xLMlpDU3RnUU5Jb3ZyazhnYlNVWnpGR0kxbTJCazZ2YXhIUFNsbFRxdk5tQVhTOHY0WnY4dl9qRWNlOWV1S25ZOF81RzROMVNSM21tVDdNd1hzVGx2MjJIRDYzdnoxMUVKWEVsbWFrbTF0SUtWQnZFN256dk9iUmcxM045blVRc3ptRnRYM2F0QUowczdlcVpyeGZtNGt3QUpoN01EUUxXR3JCWVlpZjRhUzRqV0NIOFF0Ug?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Connect Biopharma raises $20.2M, extends cash runway into 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQRHk3dEp3VVBuazhuYVo4Y1ppSXhqVjlnVkRfa2JQdk44UnlET3UyaWllS0N5US1IbzBlYy16WGxBdTNIUmJxOFV3dzZQeHdWVDFqMEhtQTFhSm9FajRTQUZjeEE3TG1HNGR6S3EzWHhDbDViVlpqT1BPUVZVOWh0Z1NVMmVjVkJFVjF6anVnZDZsUEl6T0RIWWt3UmJjQllhSDN3TXRTWWVxeVhPcWdnQzE2MA?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Announces $20.2 Million Private Placement Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQQ1BhcVhzRFdfZjk3Um0tLXE4STByeWlvS19sSjVJMFEwT1YtdnJmVTU4WDlGR2F1MzN0V0RKMmY1LTlEZkpxbXJVbFdycGs5a0g3T004aXJFYm9Cc3l3VWdoYnhwZ0s3VDh0OGh2LUo5U0lwWnQtUzFtZk00VTFXWER5UVBxRjNsYXVNanFRREcyeklhOWtodEVDbFFZWEVTdWRn?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Connect Biopharma Partners with NFL Legend Ickey Woods and the Javonte Woods Foundation to Improve Asthma Education", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPaWs0NGxSR1pHTmJDU3VZaFFQcmRVRUZvWWhZWlU5TlNPQWpLeUVJOFBNbU83T3M0QXRYMk5rWkx1dkFiS3pfcEYyWDVTNkc0eFJxRlY0VGRZVTQtd04yTWZ0NU1ZMGF3b01UVmFwbV9nQ0VpZUZnUFJzUGktWW4wcGJUQ2VSTV9ZLVdSUXd2c3dKai13ZTV0UFBfcnl1OEtDMnpYN0R5OWdyemM3WlNtZzM0VW9jN0J1OWJDYmJUUUdiazVobTJhYkFR?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2025-08-14T07:00:00+00:00", "published_display": "14 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Connect Biopharma Holdings (CNTB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9IU1pHSVMxZmhXNzJjbm93SHc1MDZSZGJVaHIzcmFQcHphQnRnc1NfSVBrRjVkcUpBU0JMbEh3aEFoRjJSLWlVOXEtNmk1Mm1ZWHk0VGRVSlZFR1JTb0s2X2xibmd1SlZEMENuag?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-07-30T07:00:00+00:00", "published_display": "30 Jul 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma (CNTB) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9jY3NnRG9ySWFxaVJaWFJmTUFDbWZEM0JUWWhmNXNMYldDaTVqOFhTZXZ6X3ZPako2cXRvVW4tVnYzZ1I2bTNmaHFicXhPdEpVUWtsT3ZXaEE4eE5JNU1SM1RnSEhPUQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T13:45:32+00:00", "published_display": "11 May 2024 13:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Connect Biopharma Stock Is Crashing Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNOUJ5dmV5TEpXckktc0h3SFBuNkUxak9sYmpZdFFqQ2M1emJNb3VrbGljWDIwbGNXRFJ5cElmOGROTGRkaEJRUDB3N2l2TGdjX1JzWEo1TFRvYllwZTVjZkt0VnRCRUhRX1J3QUtFQTgtUnRBZHNpcFdFTHRjbVZNcWkxMlNMZy1Za0ZUQWlBeldhdw?oc=5", "source_name": "The Motley Fool", "published_at": "2021-11-19T08:00:00+00:00", "published_display": "19 Nov 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CNTB: Connect Biopharma Holdings Ltd - ADR Latest Stock Price, Analysis, News and Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTE9pLVM3dnl6bS1BVkFHTlhiSTBEMV9LZjFBcTgzdkRJak1lZENxMHRnOHExN0tDT2Q4QzVfSTF4R2JIelc0NFpEWWRn?oc=5", "source_name": "Stocktwits", "published_at": "2021-07-13T11:19:20+00:00", "published_display": "13 Jul 2021 11:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings (CNTB) Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE1pUkh4cG9PNXJESDNtT3dsSzJ6Sld1UHZFN1JDSDBJbFBkZWJmcG1ncnBlZEUzVmJlQ2JKV3owT2ZfTnFqc19BZEZCV0Zqdw?oc=5", "source_name": "Stock Titan", "published_at": "2021-05-12T12:02:32+00:00", "published_display": "12 May 2021 12:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma (CNTB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5BY1lMMWF0YTlZMlFIdWFSRkdSV1lxOXBWMFdjRGtDX3BwUlMxS3UyOXR3TnVxQjNILVBSZldqTzZrdi1Yb1d1V3Nfa1JRRUh1YjZZVGhaNV8zZw?oc=5", "source_name": "MarketBeat", "published_at": "2021-03-19T23:10:54+00:00", "published_display": "19 Mar 2021 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Lake Street Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $9", "summary": "Lake Street maintained a Buy rating on Connect Biopharma (CNTB.US) and kept its target price at $9.", "url": "https://www.moomoo.com/news/post/73023632/lake-street-maintains-connect-biopharma-cntbus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-15T17:10:28", "published_display": "15 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings (CNTB) Receives a New Rating from Oppenheimer", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQTElsSVdFNC1PWXhQa2xnazJraFc0U1RYYkV3R0FLaWhvV0pDVU10eE5yVmpTRDJkS2hhYjhmZUFwVDBqTDRCVGJtNl9mcVVMWWk3NFgyckFadjBFZjJBSGZoUTdtRXo3azg3M3hWcUx6OWpnTkZaem0wVFJIbjRZWFc1TWJXU0VlLUZrYzA5OGtxRjFublFoZ0lGeFZiYWh3UmxCLXJQTVNnNVJ5T25hYnZpY01WeWJMZ0w4YlJ6U0YyNWFOZUNJaHpIOXpOSGhPRExlQ0QteEpkMVpVVkNVeWNVcXV2Zw?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-10T17:38:00+00:00", "published_display": "10 Jul 2026 17:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Initiates Connect Biopharma(CNTB.US) With Buy Rating, Announces Target Price $8", "summary": "Oppenheimer has initiated coverage on Connect Biopharma (CNTB.US) with a 'Buy' rating. The firm has set a price target of $8 for the company's stock, indicating a positive outlook for its future performance.", "url": "https://www.moomoo.com/news/post/72730067/oppenheimer-initiates-connect-biopharma-cntbus-with-buy-rating-announces-target", "source_name": "Moomoo", "published_at": "2026-07-10T14:10:24", "published_display": "10 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer initiates Connect Biopharma stock with outperform rating", "summary": "Oppenheimer has initiated coverage on Connect Biopharma (NASDAQ: CNTB) with an Outperform rating and an $8.00 price target, citing the company's lead drug rademikibart for inflammatory respiratory diseases. The drug, a next-generation human IgG4 anti-IL-4R\u03b1 antibody, is currently", "url": "https://www.investing.com/news/analyst-ratings/oppenheimer-initiates-connect-biopharma-stock-with-outperform-rating-93CH-4784101", "source_name": "Investing.com", "published_at": "2026-07-09T13:40:23", "published_display": "09 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Initiates Connect Biopharma at Outperform With $8 Price Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNcUZHdC14ZmtORGFBNlRHN2I0UkxBNF92emswWDkyb1k0SkQyTDhBOE54VHc5a3MtZTVickhKWkEtZHktdkgtS3lqbXdFaVRqb3EycWlOODFadFZmaDRfODVsRGRWNzlKcVRsMXhOanBzTXlLYW5SZlhmSzlzbzNHOHNqZ3BYZkF1RDJyQzZ2WjByb1lXVnZPclE5ZGhyN3hJMkw0TXVBZC1IcXBCdVJFVzdYQlFPNGcwM255U19MZjJGcTct?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-09T12:39:18+00:00", "published_display": "09 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer initiates Connect Biopharma stock with outperform rating By Investing.com", "summary": "Oppenheimer has initiated coverage on Connect Biopharma Holdings Ltd (NASDAQ: CNTB) with an Outperform rating and an $8.00 price target. The company is developing rademikibart for inflammatory respiratory diseases, with Phase 2 trial results for asthma and COPD expected in the se", "url": "https://ng.investing.com/news/stock-market-news/oppenheimer-initiates-connect-biopharma-stock-with-outperform-rating-93CH-2593202", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T13:10:39", "published_display": "09 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CNTB - Connect Biopharma Holdings Ltd Dividends", "summary": "This page provides detailed financial information for Connect Biopharma Holdings Ltd (CNTB), including dividend data, key financial ratios, performance metrics, and insider/institutional ownership. The company's last close was $2.36, experiencing a 4.07% decrease. It also shows v", "url": "https://finviz.com/stock?t=CNTB&ta=1&p=d&ty=dv&b=2", "source_name": "Finviz", "published_at": "2026-07-06T00:39:51", "published_display": "06 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CNTB - Connect Biopharma Holdings Ltd Latest SEC Filings", "summary": "This article provides the latest SEC filing information for Connect Biopharma Holdings Ltd (CNTB), alongside comprehensive financial data and performance metrics. It includes details such as market capitalization, income, sales, various financial ratios, insider and institutional", "url": "https://finviz.com/stock?t=CNTB&p=m&ty=lf&page=3", "source_name": "Finviz", "published_at": "2026-07-04T09:40:30", "published_display": "04 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Connect Biopharma Holdings Ltd For: 1 July By Investing.com", "summary": "This article provides details about a Form 4 filing for Connect Biopharma Holdings Ltd, dated July 1st. It highlights the stock symbol CNTB and its performance, showing a 2.93% increase. The piece is brief and primarily serves as a notification of the filing.", "url": "https://uk.investing.com/news/stock-market-news/form-4-connect-biopharma-holdings-ltd-for-1-july-93CH-4753717", "source_name": "Investing.com UK", "published_at": "2026-07-02T11:39:31", "published_display": "02 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma (CNTB) director granted 3,738 fully vested shares as fees", "summary": "Connect Biopharma Holdings Ltd director Dr. Kleanthis Gabriel Xanthopoulos was granted 3,738 fully vested Ordinary Shares on June 30, 2026. These shares were issued in lieu of a portion of his 2026 annual board cash retainers for service during Q2 2026. Following this award, Dr. ", "url": "https://www.stocktitan.net/sec-filings/CNTB/form-4-connect-biopharma-holdings-ltd-insider-trading-activity-e8fe63c2cd17.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:39:23", "published_display": "01 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma (NASDAQ: CNTB) director receives 6,718-share award as 2026 board compensation", "summary": "Connect Biopharma (NASDAQ: CNTB) director Jean I. Liu was granted 6,718 ordinary shares as compensation for her 2026 annual board service during Q2 2026, in lieu of cash retainers. This award, calculated based on the average closing share price for 30 days preceding June 30, 2026", "url": "https://www.stocktitan.net/sec-filings/CNTB/form-4-connect-biopharma-holdings-ltd-insider-trading-activity-cbf895c6e3ce.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:39:23", "published_display": "01 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings Limited(NasdaqGM: CNTB) added to Russell Microcap Index", "summary": "Connect Biopharma Holdings Limited (NasdaqGM: CNTB) has been added to the Russell Microcap Index. This follows a previous announcement that the company was also added to the Russell 3000E Growth Benchmark. The news highlights the company's progress and increased visibility within", "url": "https://www.marketscreener.com/news/connect-biopharma-holdings-limited-nasdaqgm-cntb-added-to-russell-microcap-index-ce7f5fdedd89f120", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:39:49", "published_display": "29 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings Limited(NasdaqGM:CNTB) added to Russell 3000 Growth Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOLWYxNk9oQVk3akVESTdZU2V5SFBIR2ZjUFhwNm9Ob0hkOFZKeUdER1dhT1d6Rm03ejBLenJKaGR6OEstZmRJbUR3dlFyUmZJNUJidGIzOHF6bTJKVWNuMTRLOXJGcEFYaVFZRVA1WmVjaFoyV3pPdmszajE2NENTWHlEa0ZuM0xqYmtVdmRueWd3MHJBVjN5QmlHUlhndEl0RUZSX2EtZXJTalVJMFViNi1pRjJEMDhoa1pNR3I4cmJrdm5xdWlTSDZDZnRQZUJnMDUxdlVENA?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings Limited(NasdaqGM:CNTB) added to Russell Small Cap Completeness Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxPZlFoX1NveDlMZGlqeFdFRl85VlRYYUNjbW9oU1RyVlkxM1o4X3pSOWZCUGRaTjJuV2QyczFSM1R2aVVDX0pyOEhMRng1WTZPcmNyVEs0TzFGNHVBS3kzQ0lsdDlGTlhIR1JZa1B2V2hHOVJzN3JlSFpGN3dKTzJ3RnpCVGFVUXVSWGIwSmM1R2pka1dZTTlEZ0I5MUtESkJHQkFIODZUS210UFZ6LXB1N0tDTFF1b0ZiZEZURGhwV3lQVXFUZnRSRzNGSjNxRnEtVHUzd01rTFBSQ3I0Ykx5Qw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler initiates Connect Biopharma stock with overweight rating By Investing.com", "summary": "Piper Sandler initiated coverage on Connect Biopharma Holdings Ltd (NASDAQ:CNTB) with an Overweight rating and a $7.00 price target. The firm highlighted rademikibart's potential as a unique biologic for acute asthma and COPD exacerbations, expecting significant sales growth and ", "url": "https://ca.investing.com/news/stock-market-news/piper-sandler-initiates-connect-biopharma-stock-with-overweight-rating-93CH-4708850", "source_name": "Investing.com Canada", "published_at": "2026-06-26T09:09:42", "published_display": "26 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Initiates Connect Biopharma(CNTB.US) With Buy Rating, Announces Target Price $7", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOOHljWTdtOVMydERUTjhrTmtFRFdJRm1EWUlFa0lpUDN6b3I2REdUMmozZEkxNFJUNC03SzFLdTF5aTBFdUFOZzRObHBaZ0lILVMxRXozeEdnZ1RMM2FsWEw1Nll4UEhGTlNqeTZXREw5c2xydkl5c0c4azU1WUthbWZiRG1YRi1BcEM5S3ZOdlNfdk0wb3hYVGdsYkFaYWY5bHpVaTl5MjZ5N1UzUE1UY3Z0QUNHWm8?oc=5", "source_name": "Moomoo", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler initiates Connect Biopharma stock with overweight rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNT25nOWhNVXAxV3VWUE5nN0luLXdJYTR6NXg5VEQzWjFUYURuTWxwZ0pPTFVYU2JZWGJ4ZF8xRzVYNTAtSE9BdFRVZm1OMS00dDZxV2d0eFAwVE5NRFZadVl5cmdKMGc2dHpXd29XYjFuU0x4cGNYQkZSMVMxODdfWE95RGI3eUhjUVUyc0JLdnc1WDhMNzdXNDZYbjBVcUc2dkNrSGR5aHlLMm40X0lLRmtUSnNkb09CWjRhR1pPTEhOaklHR20wWEpR?oc=5", "source_name": "Investing.com", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings Ltd. Actuals & Estimates (NASDAQ:CNTB)", "summary": "This article provides an overview of Connect Biopharma Holdings Limited (NASDAQ: CNTB) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It details financial data such as earnings per share, revenue, net income, and EBITDA, ", "url": "https://www.tradingview.com/symbols/NASDAQ-CNTB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:09:42", "published_display": "26 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Buy on Connect Biopharma stock at $7", "summary": "H.C. Wainwright has reiterated a Buy rating for Connect Biopharma Holdings Ltd (NASDAQ:CNTB) with a $7.00 price target, though InvestingPro data suggests the stock is currently overvalued. The company is actively progressing with its Phase 2 Seabreeze STAT Asthma and COPD studies", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-on-connect-biopharma-stock-at-7-93CH-4760390", "source_name": "Investing.com", "published_at": "2026-06-25T11:40:13", "published_display": "25 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings Ltd (CNTB) Valuation: PE, PB & Fair Value Analysis", "summary": "Connect Biopharma Holdings Ltd (CNTB) currently holds a valuation score of 6.10, ranking 355 out of 387 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -1.79, indicating it is -34.93% below its recent high and -131.62% above its recent low. Key", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cntb/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-24T07:42:05", "published_display": "24 Jun 2026 07:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings Ltd (CNTB) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Connect Biopharma Holdings Ltd (CNTB) has an earnings forecast score of 8.67, ranking 71st in the Biotechnology & Medical Research industry, with an average price target of $7.50. Analysts, based on 7 ratings, largely recommend a \"Buy\" for the stock, forecasting an expected reven", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cntb/earnings", "source_name": "TradingKey", "published_at": "2026-06-23T07:42:05", "published_display": "23 Jun 2026 07:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Buy on Connect Biopharma stock at $7 By Investing.com", "summary": "H.C. Wainwright has reiterated a Buy rating and a $7.00 price target for Connect Biopharma Holdings Ltd (NASDAQ:CNTB), noting a significant upside potential from its current trading price of $2.08. The firm highlighted that enrollment for the Phase 2 Seabreeze STAT COPD study is ", "url": "https://m.in.investing.com/news/stock-market-news/hc-wainwright-reiterates-buy-on-connect-biopharma-stock-at-7-93CH-5461553?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-06-18T17:09:35", "published_display": "18 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings Ltd (CNTB) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Connect Biopharma Holdings Ltd (CNTB), listing its major shareholders and their respective proportions. It also breaks down shareholder types by category, such as venture capital and corporations. Additionally, the report provides", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cntb/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:56", "published_display": "18 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings Ltd (CNTB) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for Connect Biopharma Holdings Ltd (CNTB). It states that the company has distributed $0.00 in dividends over the past five years and shows no historical data for stock splits. The stock's current price and mar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cntb/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:11:11", "published_display": "17 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma stock rises after Phase 2 asthma study enrollment By Investing.com", "summary": "Connect Biopharma Holdings Ltd (NASDAQ: CNTB) shares rose 8% after announcing the completion of enrollment in its Phase 2 Seabreeze STAT Asthma study for rademikibart. The company expects to report topline data from this study in early September 2026, followed by results from its", "url": "https://ng.investing.com/news/stock-market-news/connect-biopharma-stock-rises-after-phase-2-asthma-study-enrollment-93CH-2563373", "source_name": "Investing.com Nigeria", "published_at": "2026-06-17T15:26:00", "published_display": "17 Jun 2026 15:26", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma completes asthma trial enrollment", "summary": "Connect Biopharma Holdings Limited has completed enrollment for its Phase 2 Seabreeze STAT Asthma study, evaluating rademikibart for acute asthma exacerbations. The company expects to release topline data from the asthma study in early September 2026 and plans to meet with the FD", "url": "https://www.investing.com/news/company-news/connect-biopharma-completes-asthma-trial-enrollment-93CH-4747438", "source_name": "Investing.com", "published_at": "2026-06-17T14:11:11", "published_display": "17 Jun 2026 14:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/connect-biopharma-announces-completion-enrollment-130000017.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T13:00:00+00:00", "published_display": "17 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Completes Enrollment in Phase 2 Seabreeze STAT Asthma Study and Anticipates Upcoming COPD Study Data", "summary": "Connect Biopharma Holdings Limited has completed enrollment in its Phase 2 Seabreeze STAT Asthma study for rademikibart, a next-generation antibody for asthma exacerbations. The company expects to report topline results from the asthma study by early September 2026, with data fro", "url": "https://www.quiverquant.com/news/Connect+Biopharma+Completes+Enrollment+in+Phase+2+Seabreeze+STAT+Asthma+Study+and+Anticipates+Upcoming+COPD+Study+Data", "source_name": "Quiver Quantitative", "published_at": "2026-06-17T13:12:00", "published_display": "17 Jun 2026 13:12", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Announces Completion of Enrollment of", "summary": "Connect Biopharma has announced the completion of enrollment for its Phase 2 Seabreeze STAT Asthma study, evaluating rademikibart for acute asthma exacerbations. The company expects to report topline data from this study in early September 2026 and is on track to complete enrollm", "url": "https://www.globenewswire.com/news-release/2026/06/17/3313482/0/en/connect-biopharma-announces-completion-of-enrollment-of-phase-2-seabreeze-stat-asthma-study-evaluating-rademikibart-for-the-treatment-of-acute-exacerbations-in-asthma.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T13:10:33", "published_display": "17 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 94, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma finishes asthma study enrollment, data due in September", "summary": "Connect Biopharma has completed enrollment for its Phase 2 Seabreeze STAT Asthma study, which evaluates rademikibart for acute asthma exacerbations, and expects topline data in early September 2026. The company also anticipates completing enrollment for a related COPD study this ", "url": "https://www.stocktitan.net/news/CNTB/connect-biopharma-announces-completion-of-enrollment-of-phase-2-21qe7f6d4kk1.html", "source_name": "Stock Titan", "published_at": "2026-06-17T13:10:33", "published_display": "17 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director-linked fund boosts Connect Biopharma (NASDAQ: CNTB) stake", "summary": "An entity linked to Connect Biopharma director James Huang, Panacea Venture Healthcare Fund II, L.P., purchased 150,000 Ordinary Shares of Connect Biopharma (NASDAQ: CNTB) at a weighted average price of $2.4774 per share. This transaction increases the fund's indirect holdings to", "url": "https://www.stocktitan.net/sec-filings/CNTB/form-4-connect-biopharma-holdings-ltd-insider-trading-activity-5b23ed14ca15.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:09:52", "published_display": "02 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Connect Biopharma Holdings Ltd SEC Filing", "summary": "Connect Biopharma Holdings Ltd (NASDAQ: CNTB) announced that its F-3 shelf registration statement became effective on June 1, 2026, at 4:00 PM. The filing, dated June 2, 2026, specifies the company's CIK as 0001835268 and file number 333-295921. This indicates the company can off", "url": "https://www.stocktitan.net/sec-filings/CNTB/effect-connect-biopharma-holdings-ltd-sec-filing-f9d1dc4ab6dd.html", "source_name": "Stock Titan", "published_at": "2026-06-02T10:09:52", "published_display": "02 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings (NasdaqGM:CNTB) Stock Forecast & Analyst Predictions", "summary": "Connect Biopharma Holdings (CNTB) is projected for significant growth, with earnings forecast to increase by 2.2% and revenue by 52.7% per annum. The company's lead product, rademikibart, has shown promising results in clinical trials for atopic dermatitis, asthma, and COPD, with", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cntb/connect-biopharma-holdings/future", "source_name": "Simply Wall Street", "published_at": "2026-05-26T21:39:39", "published_display": "26 May 2026 21:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord Genuity Initiates Connect Biopharma at Buy With $6 Price Target", "summary": "Canaccord Genuity has initiated coverage on Connect Biopharma (NASDAQ: CNTB) with a Buy rating and a price target of $6. The firm's positive outlook suggests confidence in the biopharmaceutical company's future performance and potential for stock appreciation.", "url": "https://www.moomoo.com/news/post/70566398/canaccord-genuity-initiates-connect-biopharma-at-buy-with-6-price?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-26T19:09:29", "published_display": "26 May 2026 19:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Touts Rademikibart\u2019s Edge as SEABREEZE Data Looms in 2026", "summary": "Connect Biopharma's CEO, Barry Quart, highlighted the differentiated clinical profile of their rademikibart program, an IL-4 receptor alpha monoclonal antibody, as the company anticipates SEABREEZE study data in mid-2026. Quart discussed the drug's abilities to lower eosinophils ", "url": "https://es.tradingview.com/news/marketbeat:3e81f6b06094b:0-connect-biopharma-touts-rademikibart-s-edge-as-seabreeze-data-looms-in-2026/", "source_name": "TradingView", "published_at": "2026-05-25T09:09:06", "published_display": "25 May 2026 09:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Connect Biopharma Holdings (NASDAQ:CNTB) Must Use Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Could Be Quite Risky", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/companies-connect-biopharma-holdings-nasdaq-134008153.html", "source_name": "Simply Wall St.", "published_at": "2026-05-15T13:40:08+00:00", "published_display": "15 May 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxOd2lvRDFQbVQtV3R0NDcxN2JRc08tVC1xdDBiNW93ZXN1TmJWakdNcmtiOE9PNWpCYjZtQ0ZKQk10MjI0clRHbmpGQzdCSlE3T09GdzhuVUNZRDRHVUJYeVJVVktRQjlXN0I2TWduM0ktdmFkVjhLY01jWFkyM3RYWmVjZDVQMmJwcHloWVVicS1MdG9QQjFqMWo3RG5yOU1rQVBXTGltdXZTTV9yUTJnTVJmeGJ0MW5yRjROTHNBc29HNU1yek5CUVpzRkptNDZCQXZsa3JmdTZJejVuQzhnRzZrUXQ5WWJ3RUc2VWFQMkpBdEJ5enhn?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxNRk1EUDV6US1sakdvWTBiV2llQkktWGF1cnY0MFAtVUZpdGtoOWJmMDJ6bHhOM2RrMkFXVGxsaGR2YmE5cXhRdUQ0Skdia25LQ0RjZjJsNlBNd0NGSS1OSVNUSHZmOC1DLXAtZVk3UWtrR1NWTnY3aURtU1R2dF9oSG96dnp0Sm9QajJUeXZURkp6UHRSZjMtdVFSZUs0bkI2QmtDMDBGOUc1enJ6SzE4R2hzejlGa2tEbzlod0F0TVl4bkxjZGxJX0xyWWJ0Q1NncG1ZcVdTbXpoMTFacjhKQ05jYnlLUEdHaFJwcXlXUkx1cTdDUUE?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Announces Enrollment in Phase 2 Seabreeze", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAJBVV95cUxPSlVKaUJZR0Y5d3Z4OWNXejJ4V0taT2RObGpjNGgySmFScTljWWZGTnBRbW5TaXlia3FRb0pkYldFMkxaYkRqUWdiZXVnTXNDVDZ6YldsOE5hSnBSeWRIYlFqdldfLVhLN3BBdkVSNlNWS3dnNmZoN2FqLWI5TGgzV0xLMlpDU3RnUU5Jb3ZyazhnYlNVWnpGR0kxbTJCazZ2YXhIUFNsbFRxdk5tQVhTOHY0WnY4dl9qRWNlOWV1S25ZOF81RzROMVNSM21tVDdNd1hzVGx2MjJIRDYzdnoxMUVKWEVsbWFrbTF0SUtWQnZFN256dk9iUmcxM045blVRc3ptRnRYM2F0QUowczdlcVpyeGZtNGt3QUpoN01EUUxXR3JCWVlpZjRhUzRqV0NIOFF0Ug?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma raises $20.2M, extends cash runway into 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQRHk3dEp3VVBuazhuYVo4Y1ppSXhqVjlnVkRfa2JQdk44UnlET3UyaWllS0N5US1IbzBlYy16WGxBdTNIUmJxOFV3dzZQeHdWVDFqMEhtQTFhSm9FajRTQUZjeEE3TG1HNGR6S3EzWHhDbDViVlpqT1BPUVZVOWh0Z1NVMmVjVkJFVjF6anVnZDZsUEl6T0RIWWt3UmJjQllhSDN3TXRTWWVxeVhPcWdnQzE2MA?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Announces $20.2 Million Private Placement Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQQ1BhcVhzRFdfZjk3Um0tLXE4STByeWlvS19sSjVJMFEwT1YtdnJmVTU4WDlGR2F1MzN0V0RKMmY1LTlEZkpxbXJVbFdycGs5a0g3T004aXJFYm9Cc3l3VWdoYnhwZ0s3VDh0OGh2LUo5U0lwWnQtUzFtZk00VTFXWER5UVBxRjNsYXVNanFRREcyeklhOWtodEVDbFFZWEVTdWRn?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Partners with NFL Legend Ickey Woods and the Javonte Woods Foundation to Improve Asthma Education", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPaWs0NGxSR1pHTmJDU3VZaFFQcmRVRUZvWWhZWlU5TlNPQWpLeUVJOFBNbU83T3M0QXRYMk5rWkx1dkFiS3pfcEYyWDVTNkc0eFJxRlY0VGRZVTQtd04yTWZ0NU1ZMGF3b01UVmFwbV9nQ0VpZUZnUFJzUGktWW4wcGJUQ2VSTV9ZLVdSUXd2c3dKai13ZTV0UFBfcnl1OEtDMnpYN0R5OWdyemM3WlNtZzM0VW9jN0J1OWJDYmJUUUdiazVobTJhYkFR?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2025-08-14T07:00:00+00:00", "published_display": "14 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Connect Biopharma Holdings (CNTB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9IU1pHSVMxZmhXNzJjbm93SHc1MDZSZGJVaHIzcmFQcHphQnRnc1NfSVBrRjVkcUpBU0JMbEh3aEFoRjJSLWlVOXEtNmk1Mm1ZWHk0VGRVSlZFR1JTb0s2X2xibmd1SlZEMENuag?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-07-30T07:00:00+00:00", "published_display": "30 Jul 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma (CNTB) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9jY3NnRG9ySWFxaVJaWFJmTUFDbWZEM0JUWWhmNXNMYldDaTVqOFhTZXZ6X3ZPako2cXRvVW4tVnYzZ1I2bTNmaHFicXhPdEpVUWtsT3ZXaEE4eE5JNU1SM1RnSEhPUQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T13:45:32+00:00", "published_display": "11 May 2024 13:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Connect Biopharma Stock Is Crashing Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNOUJ5dmV5TEpXckktc0h3SFBuNkUxak9sYmpZdFFqQ2M1emJNb3VrbGljWDIwbGNXRFJ5cElmOGROTGRkaEJRUDB3N2l2TGdjX1JzWEo1TFRvYllwZTVjZkt0VnRCRUhRX1J3QUtFQTgtUnRBZHNpcFdFTHRjbVZNcWkxMlNMZy1Za0ZUQWlBeldhdw?oc=5", "source_name": "The Motley Fool", "published_at": "2021-11-19T08:00:00+00:00", "published_display": "19 Nov 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CNTB: Connect Biopharma Holdings Ltd - ADR Latest Stock Price, Analysis, News and Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTE9pLVM3dnl6bS1BVkFHTlhiSTBEMV9LZjFBcTgzdkRJak1lZENxMHRnOHExN0tDT2Q4QzVfSTF4R2JIelc0NFpEWWRn?oc=5", "source_name": "Stocktwits", "published_at": "2021-07-13T11:19:20+00:00", "published_display": "13 Jul 2021 11:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma Holdings (CNTB) Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE1pUkh4cG9PNXJESDNtT3dsSzJ6Sld1UHZFN1JDSDBJbFBkZWJmcG1ncnBlZEUzVmJlQ2JKV3owT2ZfTnFqc19BZEZCV0Zqdw?oc=5", "source_name": "Stock Titan", "published_at": "2021-05-12T12:02:32+00:00", "published_display": "12 May 2021 12:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Connect Biopharma (CNTB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5BY1lMMWF0YTlZMlFIdWFSRkdSV1lxOXBWMFdjRGtDX3BwUlMxS3UyOXR3TnVxQjNILVBSZldqTzZrdi1Yb1d1V3Nfa1JRRUh1YjZZVGhaNV8zZw?oc=5", "source_name": "MarketBeat", "published_at": "2021-03-19T23:10:54+00:00", "published_display": "19 Mar 2021 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 58, "sentiment_summary": {"positive": 26, "negative": 1, "neutral": 31, "score": 61, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 73, "events": [{"event": "general", "label": "Market update", "weight": 11.35, "count": 20}, {"event": "earnings", "label": "Earnings", "weight": 7.01, "count": 15}, {"event": "analyst", "label": "Analyst action", "weight": 6.6, "count": 12}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.2, "count": 4}, {"event": "guidance", "label": "Guidance", "weight": 2.2, "count": 4}, {"event": "capital_return", "label": "Capital return", "weight": 1.1, "count": 2}], "positive_events": 26, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 2.38, "latest_week": "2026-07-17", "one_week_move": -5.2, "four_week_move": 19.0, "twelve_week_move": -5.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.538995, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": 2.7, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 53.8667, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-5.2% over one week, +19.0% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 69, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 7}, {"label": "Stock Titan", "count": 7}, {"label": "GlobeNewswire", "count": 5}, {"label": "Moomoo", "count": 4}, {"label": "Investing.com", "count": 4}, {"label": "TradingKey", "count": 4}, {"label": "marketscreener.com", "count": 3}, {"label": "TradingView", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 20}, {"label": "Earnings", "count": 15}, {"label": "Analyst action", "count": 12}, {"label": "Balance sheet", "count": 4}, {"label": "Guidance", "count": 4}, {"label": "Capital return", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "61/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "73/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-5.2% over one week, +19.0% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Lake Street Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $9"}], "updated_at": "2026-07-23T05:42:14.739500+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}